TNF and diabetic kidney disease: Increasing the level of adiponectin using RAAS blockers might improve the anti-inflammatory response in DKD by activating the AMPK and cyclooxygenase-2 pathways, and decreasing tumor necrosis factor-α (TNF-α) activity.